UBS Reiterates Buy Rating on Oruka Therapeutics (ORKA) Following Data Readout
Tweet Send to a Friend
UBS analyst Michael Yee reiterated a Buy rating and $50.00 price target on Oruka Therapeutics (NASDAQ: ORKA).The analyst commented, "ORKA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
